Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–2726.

• PubMed
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–2726.15187053)| false
• Search Google Scholar
• Export Citation

Unger JM, Fleury M. Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer. J Clin Oncol 2021;39:74.

• PubMed
Unger JM, Fleury M. Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer. J Clin Oncol 2021;39:74.)| false
• Search Google Scholar
• Export Citation

Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019;111:245–255.

• PubMed
Unger JM, Vaidya R, Hershman DL, Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019;111:245–255.30856272)| false
• Search Google Scholar
• Export Citation

Comis RL, Miller JD, Aldigé CR, et al. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003;21:830–835.

• PubMed
Comis RL, Miller JD, Aldigé CR, Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003;21:830–835.12610181)| false
• Search Google Scholar
• Export Citation

Unger JM, Hershman DL, Till C, et al. “When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. J Natl Cancer Inst 2021;113:244–257.

• PubMed
Unger JM, Hershman DL, Till C, “When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. J Natl Cancer Inst 2021;113:244–257.33022716)| false
• Search Google Scholar
• Export Citation

Jorge S, Masshoor S, Gray HJ, et al. Participation of patients with limited English proficiency in gynecologic oncology clinical trials. J Natl Compr Canc Netw 2023;21:27–32.

• PubMed
Jorge S, Masshoor S, Gray HJ, Participation of patients with limited English proficiency in gynecologic oncology clinical trials. J Natl Compr Canc Netw 2023;21:27–32.36634612)| false
• Search Google Scholar
• Export Citation

Muthukumar AV, Morrell W, Bierer BE. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov. PLoS Med 2021;18:e1003758.

• PubMed
Muthukumar AV, Morrell W, Bierer BE. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov. PLoS Med 2021;18:e1003758.34520467)| false
• Search Google Scholar
• Export Citation

Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106:dju244.

• PubMed
Basch E, Reeve BB, Mitchell SA, Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106:dju244.25265940)| false
• Search Google Scholar
• Export Citation

Minasian LM, Unger JM. What keeps patients out of clinical trials? JCO Oncol Pract 2020;16:125–127.

• PubMed
Minasian LM, Unger JM. What keeps patients out of clinical trials? JCO Oncol Pract 2020;16:125–127.32074016)| false
• Search Google Scholar
• Export Citation

Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 2019;5:e191870.

• PubMed
Loree JM, Anand S, Dasari A, Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 2019;5:e191870.31415071)| false
• Search Google Scholar
• Export Citation